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Abstract
Prompt initiation of combination antiretroviral therapy (ART) is important to reduce comorbid-
ity and mortality among people living with HIV, especially for those with a low CD4 cell count.
However there is evidence that not everyone receives prompt initiation of ART after enrolling
into HIV care. The current study investigated factors associated with failure to initiate ART
within two years of entering into care among those with a CD4 count at or below 350 cells/
mm3. The sample included 4,907 ART-naive patients with a CD4 count at or below 350 cells/
mm3 enrolled between January 1, 2003 and December 31, 2012 at any of eight clinical sites
in the Center for AIDS Research Network of Integrated Clinical Systems (CNICS). The two-
year risk of delayed ART initiation was estimated using a log-binomial regression model with
stabilized inverse probability of censoring weights for those lost to follow-up. Adjusting for
other factors, an earlier enrollment date was the sole demographic characteristic associated
with an increased risk of delayed ART initiation. Higher CD4 count, lower viral load, and a
prevalent AIDS diagnosis were clinical characteristics associated with delayed ART initiation.
Gender, age, race/ethnicity and HIV risk factors such as reported male-to-male sexual con-
tact and injection drug use were not associated with delayed ART initiation. This study identi-
fied characteristics of patients for whom treatment was strongly to moderately recommended
but who did not initiate ART within two years of entering care. Despite the known benefits of
early antiretroviral therapy initiation, a lower viral load measurement may continue to be an
important clinical characteristic in the more recent era with current ART initiation guidelines.
These findings provide a target for closer monitoring and intervention to reduce disparities in
HIV care.
Introduction
Despite the introduction of effective combination antiretroviral therapy (ART) for HIV in
1996 [1], HIV continues to be a global health crisis. For example, in 2014, the United States
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Centers for Disease Control and Prevention (CDC) estimated 1.2 million US persons living
with HIV and 12,333 AIDS-related deaths [2]. The use of ART has led to an increase in life
expectancy among HIV-seropositive individuals through a reduction in HIV-associated
comorbidity, as well as non-HIV and non-AIDS comorbidities [3–6]. The difference in life
expectancy between HIV-seropositive and HIV-seronegative individuals is shrinking, though
specific populations still exhibit notable differences [3, 6]. For example, among HIV-seroposi-
tive patients on ART, those with a history of injection drug use, a lower baseline CD4 count,
and who are non-white have lower life expectancies relative to other groups [3, 6]
The current guidelines provided by the US Department of Health and Human Services
(DHHS) recommend that ART be provided to all HIV-seropositive individuals to reduce dis-
ease progression and prevent HIV transmission [5]. While several studies have assessed char-
acteristics associated with a faster time to ART initiation using time-to event analyses, we
know of no other studies assessing the proportion of patients promptly initiating ART and
their characteristics, especially among those for whom treatment was strongly to moderately
recommended [7–10]. Some characteristics associated with a slower time to ART initiation
include black non-Hispanic race/ethnicity, injection drug use, a greater number of psychoso-
cial barriers, female gender, reporting male-to-male sexual contact, lack of health insurance,
higher CD4 count, and lack of comorbidity [7–10]. A prior study among participants in the
HIV Outpatient Study found that 20% of HIV-seropositive patients did not initiate ART
within a 13.5-year study period from 2000–2013 [10]. Evidence from other countries looking
at the proportion of patients initiating ART and their characteristics also suggests that not all
HIV-seropositive individuals obtain prompt initiation of ART, even among those who have
entered care [11,12]. It is unclear whether these same characteristics associated with a faster
time to ART initiation among all HIV-seropositive patients are consistent characteristics of
delayed ART initiation among those recommended for treatment. Pinpointing characteristics
of those patients indicated for ART initiation, but who have not initiated ART, is especially rel-
evant given current clinical guidelines that recommend treatment for all HIV-seropositive
patients. A prior study using a clinic-based cohort in Uganda found that 18% of HIV-seroposi-
tive patients did not initiate ART within one year of their ART eligibility [12]. While younger
age, male sex, higher CD4 count, no formal education, and being employed have been impli-
cated as predictors of delay, there is not yet consensus about risk factors for delayed ART initi-
ation [5, 9–12].
Here we report the proportion of HIV-seropositive patients with a CD4 count at or below
350 cells/mm3 who do not start ART within two years of entry to care during the study period
between 2003 and 2012, using data from the Centers for AIDS Research Network of Integrated
Clinical Systems (CNICS). Though HIV/AIDS clinical guidelines did not recommend ART
initiation for all HIV-seropositive patients during this study period, treatment for individuals
with a CD4 count at or below 350 cells/mm3 shifted from a moderate to strong recommenda-
tion over this time period [13, 14]. We further compare characteristics at care entry of HIV-
seropositive patients who had initiation delayed to those who did initiate ART within two
years of care entry. We hypothesized that characteristics associated with lack of adherence to
ART, such as younger age and a history of injection drug use, would be associated with delay
of ART initiation among those with a strong to moderate recommendation for treatment.
Materials and methods
Study sample
CNICS is designed to support population-based HIV research through a comprehensive, stan-
dardized clinical data repository from point-of-care electronic medical records. CNICS
Risk factors for delayed ART initiation
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includes clinical data from over 30,000 HIV-seropositive adults, aged 18 years and older, who
initiated primary care after January 1, 1995 at any of eight CNICS sites in the US. These sites
include Case Western Reserve University, Fenway Community Health Center of Harvard Uni-
versity, Johns Hopkins University, University of Alabama at Birmingham, University of Cali-
fornia at San Diego, University of California at San Francisco, University of North Carolina,
and University of Washington. Institutional review boards at each site approved study partici-
pation. Participants provided written informed consent or a waiver of informed consent to use
clinical and administrative data, as approved by the local institutional review board. CNICS
maintains data on patient demographics, disease diagnoses, laboratory data, medication data,
health care utilization, vital status, patient reported outcomes, and antiretroviral drug resis-
tance. Historical data on patients’ prior ART and diagnosis history are collected at the time of
enrollment, which is at the time of their second clinic visit. Mortality is confirmed from clinic
sources, death certificates, and the US Social Security Death Index, which is regularly checked
by CNICS sites. Follow-up data are acquired at clinic visits, which are approximately every
three months on average.
In this prospective cohort study, the analysis was restricted to HIV-seropositive patients
with a baseline CD4 count at or below 350 cells/mm3, enrolled in CNICS between January 1,
2003 and December 31, 2012, and who had not initiated ART prior to their CNICS enrollment.
Overall, 6,083 patients met these study eligibility criteria. There were 861 patients (14%)
excluded due to missing data at baseline including missing HIV-1 RNA viral load (n = 147,
2%), race/ethnicity (n = 588, 10%), and HIV risk factors such as reported injection drug use
(n = 155, 3%), and reported male-to-male sexual contact (n = 125, 2%). Patients with a viral
load measurement of less than 75 copies/mL indicative of suppressed or undetectable viral
load (n = 315, 5%) were excluded because many of these patients may have been misclassified
as ART-naïve. Patient characteristics among those excluded followed a similar distribution to
those included in the final study sample. This resulted in a final study sample of 4,907 patients.
Outcome definition
The primary outcome, delayed ART initiation, was defined as failure to initiate a regimen of
three or more antiretroviral drugs within the first two years of CNICS enrollment. The date of
ART initiation was determined to be the first day in which each patient was prescribed three
or more antiretroviral drugs.
Patient characteristics
The following factors were assessed as predictors of delayed ART initiation: age (18–29, 30–34,
35–39, 40–44, 45–49, and 50–93 years), gender (male/female), race/ethnicity (white non-His-
panic, black non-Hispanic, other non-Hispanic, and Hispanic), enrollment date (in years),
HIV transmission risk factor of injection drug use (yes/no) and male-to-male sexual contact
(yes/no), AIDS diagnosis (yes/no), HIV-1 RNA viral load (75–9,999, 10,000–99,999, and
100,000–1.6x106 copies/mL), and CD4 cell count (0–199 and 200–350 cells/mm3). Age, injec-
tion drug use, male-to-male sexual contact, calendar year, and AIDS diagnosis were defined at
study enrollment. HIV-1 RNA viral load and CD4 cell count were defined as the most recent
lab measurement recorded within 90 days prior to 30 days after study enrollment.
Statistical analysis
Factors were summarized using percent or median with interquartile range (IQR), as appro-
priate, according to ART initiation status, lost-to-follow-up, and deaths. Patients were defined
as lost to follow-up at one year since their last clinic visit without a recorded lab measurement.
Risk factors for delayed ART initiation
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Stabilized inverse probability of censoring weights were constructed using two logistic regres-
sion models. The first model estimated the unconditional probability of being censored and
the second model estimated the probability of being censored conditional on all measured fac-
tors. The final weight was the marginal probability of remaining under follow-up divided by
the patient’s conditional probability of remaining under follow-up. The stabilized inverse
probability of censoring weights had a mean of 1.00 and ranged from 0.95 to 1.52. A weighted
log-binomial model was used to estimate crude and multivariable-adjusted risk ratios (RR)
comparing delayed ART initiation within two years between patients with and without each
risk factor. Confidence intervals were based on the robust variance estimator. Deaths within
the two-year ART initiation period were classified based on whether patients did or did not
initiate ART before their occurrence of death. Patients initiating ART prior to being lost to fol-
low up within the two-year ART initiation period were classified as initiating ART. The final
contrast compares those who fail to initiate ART to those who initiate ART within the two-
year period, with patients lost to follow up prior to initiating ART contributing to the weighted
model through inverse probability of censoring weights. In multivariable analyses, the RR and
95% CIs were estimated for each factor while adjusting for all other factors.
We categorized age, CD4 cell count, and viral load to relax linearity assumptions. Previous
DHHS guidelines suggest that these categories for CD4 cell count and viral load are appropri-
ate cut points for clinical decisions regarding the initiation of therapy among ART-naïve
patients [13, 14]. We assessed potential differences by calendar time in the association between
risk factors and delayed ART initiation through examination of stratified results by two enroll-
ment date periods. We conducted two sensitivity analyses comparing results with the exclusion
of decedents over the two-year risk period and then further adjusting for both clinic site and
the number of clinic visits. Data analyses were performed using SAS software version 9.3 (SAS
Institute, Inc., Cary, NC).
Results
The distribution of demographic characteristics for the sample at CNICS enrollment is dis-
played in Table 1. The majority of patients were men (83%; n = 4,084) and the prevalence of
male-to-male sexual contact was 60% (n = 2,925). Thirteen percent (n = 654) of patients
reported injection drug use and 29% (n = 1,432) of patients had a prevalent AIDS diagnosis at
their CNICS enrollment. The median CNICS enrollment year was 2007 (IQR: 2005, 2010) and
18% of patients were at least 50 years of age. Forty-two percent of patients had a viral load
100,000 copies/mL and 59% of patients had a CD4 cell count below 200 cells/mm3. The most
common racial groups were white non-Hispanic at 41%, black non-Hispanic at 40%, and His-
panic at 13%.
In their first two years of follow-up, 16% (n = 796) of the 4,907 patients did not initiate
ART, 6% (n = 303) died, 19% (n = 930) were lost to follow-up, and 59% (n = 2,878) initiated
ART. Excluding only patients who were alive and had not initiated ART prior to becoming
lost to follow-up (n = 293), the proportion that did not initiate ART within 6 months, 1 year,
and 2 years was 31% (n = 1,439), 26% (n = 1,178), and 21% (n = 959), respectively.
Table 2 presents the primary analysis of estimates of the crude and adjusted risk ratios for
delayed ART, comparing failure to initiate ART within two years of enrollment for each demo-
graphic factor. Women and those reporting injection drug use at enrollment were less likely to
initiate ART within two years following CNICS enrollment compared to men (crude RR =
1.28; 95% CI: 1.07, 1.54) and those that did not report injection drug use (crude RR = 1.27;
95% CI: 1.03, 1.56), respectively. After adjustment for other factors, an earlier CNICS enroll-
ment date was the only demographic factor associated with delayed ART initiation. For
Risk factors for delayed ART initiation
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example, for each one-year increase in CNICS enrollment date, patients were 0.94 times (95%
CI: 0.92, 0.97) as likely to delay ART initiation. Age, gender, race/ethnicity, reported injection
drug use, and an HIV risk factor of male-to-male sexual contact were not associated with
delayed ART initiation after adjustment for other factors.
Clinical factors, each assessed at enrollment, were examined as to their association with
delayed ART after adjustment for all other clinical and demographics factors. As shown in
Table 2, clinical factors associated with delayed ART included higher CD4 cell count, lower
viral load, and a prevalent AIDS diagnosis. For example, those with CD4 count at least 200
cells/mm3 at enrollment were 1.31 (95% CI: 1.11, 1.56) times as likely to delay ART initiation
compared to those with CD4 count less than 200 cells/mm3. Those with viral load less than
10,000 copies/ml at enrollment were more likely to delay ART initiation compared to those
with viral load at least 100,000 copies/ml (adjusted RR = 1.89; 95% CI: 1.53, 2.33). Finally,
those with a prevalent AIDS diagnosis at enrollment were more likely to delay ART initiation
(adjusted RR = 1.23; 95% CI: 1.04, 1.47).
Table 3 presents estimates of the crude and adjusted risk ratios for delayed ART by CD4
count, a prevalent AIDS diagnosis, and viral load over two enrollment date periods. The asso-
ciation with delayed ART for both baseline CD4 count and a prevalent AIDS diagnosis dissi-
pated in the latter time period. For example, from 2003–2007, those with CD4 count at least
Table 1. Characteristics of HIV-seropositive Patients Enrolled in CNICS, 2003–2012.
Characteristic Non-Initiators Deaths Lost to Follow-Up ART Initiators Overall
(n = 796) (n = 303) (n = 930) (n = 2878) (n = 4907)
N % N % N % N % N %
Enrollment Yeara 2007 (2005, 2009) 2006 (2004, 2009) 2007 (2005, 2009) 2007 (2005, 2010) 2007 (2005, 2010)
Gender Women 156 19.6 52 17.2 158 17.0 457 15.9 823 16.8
Age (years) <30 135 17.0 24 8.0 129 13.9 516 17.9 804 16.4
30–34 100 12.6 36 11.9 137 14.7 423 14.7 696 14.2
35–39 137 17.2 44 14.5 156 16.8 507 17.6 844 17.2
40–44 141 17.7 48 15.8 199 21.4 523 18.2 911 18.6
45–49 137 17.2 59 19.5 153 16.5 443 15.4 792 16.1
50+ 146 18.3 92 30.4 156 16.8 466 16.2 860 17.5
Race/Ethnicity
White Non-Hispanic 298 37.4 112 37.0 370 39.8 1210 42.0 1990 40.6
Black Non-Hispanic 358 45.0 139 45.9 405 43.6 1040 36.1 1942 39.6
Other Non-Hispanic 46 5.8 15 5.0 53 5.7 211 7.3 325 6.6
Hispanic 94 11.8 37 12.2 102 11.0 417 14.5 650 13.3
Injection Drug Use Yes 113 14.2 61 20.1 179 19.3 301 10.5 654 13.3
MSM Yes 441 55.4 129 42. 6 553 59.5 1802 62.6 2925 59.6
CD4 Count (cells/mm3) <200 393 49.4 241 79.5 510 54.8 1748 60.7 2892 58.9
Viral Load (copies/mL) 100,000+ 257 32.3 151 49.8 303 32.6 1340 45.6 2051 41.8
10,000–99,999 311 39.1 110 36.3 423 45.5 1061 36.9 1905 38.8
<10,000 228 28.6 42 13.9 204 21.9 477 16.6 951 19.4
AIDS Diagnosis Yes 230 28.9 141 46.5 257 27.6 804 27.9 1432 29.2
Abbreviations: CNICS, CFAR Network of Integrated Clinical Systems; MSM, ever male-to-male sexual contact; AIDS, acquired immunodeficiency
syndrome
aMedian (interquartile range)
https://doi.org/10.1371/journal.pone.0180843.t001
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200 cells/mm3 at enrollment were 1.59 (95% CI: 1.28, 1.97) times as likely to delay ART initia-
tion compared to those with CD4 count less than 200 cells/mm3. However from 2008–2012,
those with CD4 count at least 200 cells/mm3 at enrollment were 1.04 (95% CI: 0.82, 1.32) times
as likely to delay ART initiation compared to those with CD4 count less than 200 cells/mm3.
The association between viral load and delayed ART initiation was attenuated, but still per-
sisted in the latter time period. In additional sensitivity analyses, excluding decedents over the
two-year risk period and further adjusting for both clinic site and the number of clinic visits
resulted in no appreciable changes in the patterns seen in the data.
Discussion
We found that among ART-naïve patients with CD4 count at or below 350 cells/mm3, higher
CD4 count, lower viral load, a prevalent AIDS diagnosis, and an earlier CNICS enrollment
date were each independently associated with failure to initiate ART within the first two years
after enrollment in CNICS between January 1, 2003 and October 1, 2012. Lower viral load was
Table 2. Associations between risk factors and lack of ART initiation among HIV-seropositive patients with CD4 at or below 350 cells/mm3 enrolled
in CNICS (including deaths) with inverse probability of censoring weighting, 2003–2012.
Characteristic Non-Initiators ART Initiators Crude RRa
(95% CI)
Adjusted RRa
(95% CI)(n = 959) (n = 3655)
N % N %
Enrollment Yearb 2007 (2005, 2009) 2007 (2005, 2010) 0.94 (0.92, 0.97) 0.94 (0.92, 0.97)
Gender Men 772 80.5 3080 84.3 1 1
Women 187 19.5 575 15.7 1.28 (1.07, 1.54) 0.95 (0.75, 1.21)
Age (years) <30 147 15.3 609 16.7 1 1
30–34 122 12.7 534 14.6 0.96 (0.74, 1.25) 1.01 (0.76, 1.35)
35–39 161 16.8 640 17.5 1.06 (0.83, 1.36) 1.06 (0.81, 1.40)
40–44 166 17.3 676 18.5 1.03 (0.81, 1.33) 0.95 (0.74, 1.24)
45–49 165 17.2 580 15.9 1.19 (0.93, 1.53) 1.13 (0.85, 1.49)
50+ 198 20.7 616 16.9 1.34 (1.05, 1.70) 1.25 (0.95, 1.63)
Race/Ethnicity White Non-Hispanic 362 37.8 1522 41.6 1 1
Black Non-Hispanic 436 45.5 1373 37.6 1.34 (1.14, 1.57) 1.15 (0.96, 1.38)
Other Non-Hispanic 50 5.2 260 7.1 0.82 (0.59, 1.13) 0.80 (0.57, 1.14)
Hispanic 111 11.6 500 13.7 0.94 (0.75, 1.19) 0.93 (0.72, 1.20)
Injection Drug Use No 817 85.2 3208 87.8 1 1
Yes 142 14.8 447 12.2 1.27 (1.03, 1.56) 1.03 (0.81, 1.30)
MSM No 448 46.7 1410 38.6 1 1
Yes 511 53.3 2245 61.4 0.72 (0.62, 0.83) 0.82 (0.68, 1.02)
CD4 Count (cells/mm3) <200 524 54.6 2240 61.3 1 1
200–350 435 45.4 1415 38.7 1.33 (1.15, 1.53) 1.31 (1.11, 1.56)
Viral Load (copies/mL) 100,000+ 337 35.1 1642 44.9 1 1
10,000–99,999 370 38.6 1414 38.7 1.28 (1.09, 1.51) 1.23 (1.03, 1.47)
<10,000 252 26.3 599 16.4 2.06 (1.71, 2.49) 1.89 (1.53, 2.33)
AIDS Diagnosis No 655 68.3 2609 71.4 1 1
Yes 304 31.7 1046 28.6 1.16 (1.00, 1.36) 1.23 (1.04, 1.47)
Abbreviations: CNICS, CFAR Network of Integrated Clinical Systems; MSM, ever male-to-male sexual contact; AIDS, acquired immunodeficiency
syndrome; CI, confidence interval; RR, risk ratio
aIP weighted estimates
bMedian (interquartile range)
https://doi.org/10.1371/journal.pone.0180843.t002
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the sole clinical factor to remain associated with failure to initiate ART over the entire study
period. Female gender, older age, black race/ethnicity, reported injection drug use, and lack of
reported male-to-male sexual contact were demographic characteristics associated with
delayed ART initiation in the unadjusted analysis, but did these associations did not persist
after adjustment for other demographic and clinical characteristics.
The fact that entering CNICS with a CD4 count of at least 200 cells/mm3 was associated
with delayed ART initiation compared to those with CD4 count less than 200 cells/mm3 was
somewhat anticipated, but strength of this association given the extent of the delay (two years)
was greater than expected. Clinical guidelines for ART initiation among treatment-naïve HIV
patients have evolved. In 2003, at the beginning of study follow-up, ART initiation was recom-
mended for HIV-seropositive individuals with a CD4 count less than 200 cells/mm3 [13].
However the strength of recommendation for ART initiation among asymptomatic patients
with a CD4 count at least 200 cells/mm3 was carefully evaluated at the discretion of the patient
and physician, with regard to weighing potential benefits and risks of early or delayed therapy
initiation, especially among those patients with a CD4 count greater than 350 cells/mm3 for
whom the benefits of ART initiation were uncertain [13]. By 2007, guidelines recommended
ART initiation for those with CD4 count less than 350 cells/mm3 [14]. Our findings that an
earlier year of enrollment and higher CD4 count are associated with failure to initiate ART,
and that the association between higher CD4 count and delayed ART is attenuated over time
likely reflect these changes in the HIV/AIDS clinical guidelines and treatment patterns regard-
ing treatment initiation. Though guidelines also recommended ART initiation for patients
with an AIDS diagnosis, it is possible that our findings that a prevalent AIDS diagnosis was
associated with delayed ART initiation could have resulted from a lower engagement in care
among these patients. Patients with a prevalent AIDS diagnoses were more likely to receive
Table 3. Association between clinical characteristics and lack of ART initiation across two enrollment periods among HIV-seropositive patients
enrolled in CNICS (including deaths) with inverse probability of censoring weighting, 2003–2012.
Enrollment Periods Characteristic Non-Initiators
(n = 959)
ART Initiators
(n = 3655)
Crude RRa
(95% CI)
Adjusted RRa
(95% CI)
N % N %
2003–2007
CD4 Count (cells/mm3) <200 306 54.1 1247 65.4 1 1
200–350 260 45.9 659 34.6 1.62 (1.34, 1.96) 1.59 (1.28, 1.97)
AIDS Diagnosis No 364 64.3 1286 67.5 1 1
Yes 202 35.7 620 32.5 1.16 (0.95, 1.41) 1.43 (1.15, 1.77)
Viral Load (copies/mL) 100,000+ 211 37.3 921 48.3 1 1
10,000–99,999 208 36.8 717 37.6 1.28 (1.03, 1.58) 1.20 (0.96, 1.50)
<10,000 147 26.0 268 14.1 2.39 (1.86, 3.07) 2.08 (1.59, 2.71)
2008–2012
CD4 Count (cells/mm3) <200 218 55.5 993 56.8 1 1
200–350 175 44.5 756 43.2 1.06 (0.85, 1.32) 1.04 (0.82, 1.32)
AIDS Diagnosis No 291 74.1 1323 75.6 1 1
Yes 102 26.0 426 24.4 1.09 (0.85, 1.41) 1.03 (0.80, 1.34)
Viral Load (copies/mL) 100,000+ 126 32.1 721 41.2 1 1
10,000–99,999 162 41.2 697 39.9 1.32 (1.03, 1.71) 1.32 (1.01, 1.72)
<10,000 105 26.7 331 18.9 1.82 (1.36, 2.44) 1.72 (1.27, 2.32)
Abbreviations: CNICS, CFAR Network of Integrated Clinical Systems; CI, confidence interval; RR, risk ratio
aIP weighted estimates
https://doi.org/10.1371/journal.pone.0180843.t003
Risk factors for delayed ART initiation
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their AIDS diagnosis earlier in the HIV epidemic and prior to their CNICS enrollment date. It
is possible these patients may have received care but were not consistently engaged in care.
We know of no other studies in US populations investigating the proportion of patients, for
whom treatment was strongly to moderately recommended, with delayed ART initiation and
their characteristics. Given that clinical guidelines recommended ART initiation for all
patients regardless of CD4 count as of March 2012, it has become more important to charac-
terize which patients are eligible for increased benefits of treatment initiation. A study of HIV
patients newly clinically eligible for ART through their first reported CD4 count <350 cells or
an AIDS-defining illness from the NA-ACCORD between 2001 and 2009 assessed factors asso-
ciated with timely ART initiation [15]. Increasing age, later calendar year, male sex, a lack of
history of injection drug use, a lower number of psychosocial barriers, lower CD4 count,
increasing viral load, and lack of incident AIDS-defining illness were associated with a shorter
time to ART initiation [15]. They also found that none of these characteristics varied over time
in their association with a shorter time to ART initiation [15]. Our findings that some of these
characteristics are associated with delayed ART initiation within a two-year period are consis-
tent with their findings. However, our findings also suggest that the importance of clinical
characteristics associated with delayed ART initiation may be diminishing over time, within
the exception of lower viral load.
It was unexpected that race/ethnicity, gender, and a history of injection drug use were not
associated with delayed ART initiation in the adjusted analysis. During this study period, con-
cerns about the role of treatment adherence in treatment effectiveness played a pivotal role in
deciding whether to initiate treatment in ART-naïve patients [13, 14]. Previous studies have
found that blacks and women experience less time on ART while in HIV care compared to
whites and men, and that older age and male sex are associated with a shorter time to ART ini-
tiation [15, 16]. A recent study of patients from the Johns Hopkins HIV Clinical Cohort com-
pared differences in the average time for each stage of the HIV care continuum between
people who inject drugs and those who do not across 10 years following their enrollment [17].
Patients reporting a history of injection drug use spent an additional 5.5 months in HIV care
but not on ART, and an additional 5.0 months on ART but not virally suppressed compared to
those who did not have an injection drug use history [17]. Given these findings, the disparities
between gender, race, and history of injection drug use in access and barriers to care, and the
potential concerns regarding adherence to treatment, it is expected that these demographic
characteristics are associated with two-year delayed ART initiation as shown in the unadjusted
analysis. However, our results suggest that these demographic differences may be explained by
unequal distributions of adverse clinical characteristics, which appear to be stronger risk fac-
tors for treatment initiation. For example, the strength of the association between non-His-
panic black race/ethnicity and delayed ART initiation was attenuated after adjustment for
other factors.
The present work has several limitations. First, this is an observational study and therefore
estimates are subject to possible confounding bias. Multiple adjusted effects from a single
model should be interpreted with caution, and the potential for overadjustment bias, as well as
adjusting for unnecessary variables should not be overlooked as these adjustments can result
in increased bias or reduced precision [18, 19]. However the primary focus of this research was
to describe common characteristics of individuals not receiving prompt treatment with the
goal of improving HIV care.
Second, it is assumed measurements were taken with negligible error. CNICS is a clinic-
based research network using point-of-care data collection to deliver medical information
suited for research in a real-time setting using its standardized clinical repository. Given the
standardized procedures in data collection, misclassification is likely to be modest. However,
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there could be unmeasured misclassification of clinical factors, including CD4 count and viral
load, where it is possible that those patients classified as treatment-naïve could have previously
received treatment. Third, results pertain to patients enrolled in HIV care during this study
period from 2003–2012, though treatment patterns and guidelines have continued to evolve
over time. Fourth, though not included in this study, insurance status and socioeconomic sta-
tus are other patient characteristics that could be considered as potential risk factors for
delayed ART initiation.
Lastly, deaths over the two-year time period were relatively infrequent, but losses to follow
up were not. Inverse probability of censoring weights were used and we assume that the data
are missing at random such that covariate information in the data can be used to eliminate
selection bias induced by censoring individuals lost to follow up prior to therapy initiation.
A major strength of the CNICS cohort is that it is a large multicenter HIV clinical cohort
that has a standardized clinical data repository based upon prospective collection of compre-
hensive patient data. Given this strong research network, there was not a substantial amount
of missing data for any of the covariates within this study. However, the general population is
likely to include HIV-seropositive patients who are more difficult to enroll in clinical cohorts,
such as those individuals with lower access and engagement in the healthcare system. Our
results estimating the proportion of delayed ART initiation are likely to be conservative rela-
tive to other US HIV-seropositive patient populations. Future studies can help to identify
whether these same characteristics remain consistent risk factors for delayed ART initiation
among other HIV-seropositive patient populations.
Conclusions
This study identified characteristics of patients who delay ART initiation beyond the first two
years of entering in care, which included an earlier CNICS enrollment date, higher CD4
count, lower viral load, and a prevalent AIDS diagnosis. This prolonged delay in ART initia-
tion among patients with a moderate to strong recommendation under past guidelines sug-
gests that treatment practice under current guidelines recommending therapy initiation to all
HIV-seropositive patients should be carefully scrutinized. The tendency to delay therapy in
those patients with a lower viral load may still persist despite clear evidence of the benefits of
immediate therapy initiation [20]. These clinical characteristics may continue to be important
with current ART guidelines in providing targets for closer monitoring and intervention to
reduce disparities in HIV care.
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